Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 25.56% | 65.52% | 71.18% | 72.70% | 69.71% |
Total Depreciation and Amortization | -36.36% | -66.67% | -81.48% | 113.89% | -91.13% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -417.78% | -106.66% | -109.35% | -99.59% | -93.17% |
Change in Net Operating Assets | 126.72% | 168.18% | 206.49% | 386.76% | -807.18% |
Cash from Operations | -20.85% | -3.44% | 23.28% | 42.08% | 22.50% |
Capital Expenditure | -- | -175.00% | -175.00% | -120.00% | -29.41% |
Sale of Property, Plant, and Equipment | -- | -99.09% | -99.09% | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -100.00% | 522.72% | 100.00% | 100.00% | -99.89% |
Cash from Investing | -100.00% | 550.96% | -120.79% | 184.76% | -99.21% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 99.43% | -97.80% | -97.80% | 6,800.00% | 2,374.01% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -496.91% | -- | -- | -- | -- |
Cash from Financing | 90.68% | -100.00% | -100.00% | 6,651.38% | 2,320.72% |
Foreign Exchange rate Adjustments | -- | -- | -- | 109.52% | 100.00% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 82.09% | 2.68% | -49.16% | 86.63% | -97.65% |